Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

NCT06212960 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-04-04

No results posted yet for this study

Summary

To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.

Conditions

  • Glabellar Lines

Interventions

BIOLOGICAL

DWP712

Clostridium botulinum Toxin

BIOLOGICAL

BOTOX®

Clostridium botulinum Toxin

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Beom Joon Kim, MD, Ph.D · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-28
Primary Completion
2024-02-26
Completion
2024-03-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06212960 on ClinicalTrials.gov